04-13 Aptamer Sciences Inc announced that it has received KRW 30.00043989 billion in funding from Alticast Corporation, Daihyun Eng & Const Co., Ltd., K&P Investment Co., Ltd., Vision 2 Co., Ltd., JDK Partners Co., Ltd. and other investors. CI
04-08 Aptamer Sciences Inc announced that it has received KRW 12 billion in funding CI
03-24 Aptamer Sciences Inc agreed to acquire Choolip Inc. from Wellnew & Co for $11.4 million. CI
02-12 Aptamer Sciences Inc announced that it has received KRW 7 billion in funding CI
02-09 FOCUS AI Co., Ltd. announced that it has received KRW 5.423916904 billion in funding from Aptamer Sciences Inc, Nex Plan Co., Ltd., 3S E&D Co., Ltd. CI
01-27 Aptamer Sciences Inc announced that it expects to receive KRW 12 billion in funding CI
01-25 FOCUS AI Co., Ltd. announced that it has received KRW 999.999944 million in funding from Aptamer Sciences Inc CI
01-15 Aptamer Sciences Inc announced that it expects to receive KRW 7 billion in funding from Bellum Fund 1 CI
12-18 FOCUS AI Co., Ltd. announced that it expects to receive KRW 999.999944 million in funding from Aptamer Sciences Inc CI
12-02 FOCUS AI Co., Ltd. announced that it expects to receive KRW 9.42391668 billion in funding from Aptamer Sciences Inc and other investors CI
23/10/25 Alticast Corporation completed the acquisition of 8.07% stake in Aptamer Sciences Inc from Han Dong-il, Ryu Seong-ho, Jang Seung-gi. CI
07/09/25 Alticast Corporation agreed to acquire an 8.07% stake in Aptamer Sciences Inc from Han Dong-il, Ryu Seong-ho, Jang Seung-gi for KRW 4.4 billion. CI
20/08/25 Aptamer Sciences wins 320 million won order RE
1 day+11.50%
1 month-14.34%
3 months-37.17%
6 months-22.13%
Current year+25.33%
1 month 820
Extreme 820
1,115
Current year 675
Extreme 675
1,998
1 year 675
Extreme 675
1,998
3 years 675
Extreme 675
4,875
5 years 675
Extreme 675
13,875
10 years 675
Extreme 675
19,175
Manager TitleAgeSince
Chief Executive Officer 54 26/10/2025
Director of Finance/CFO 56 26/10/2025
Chief Tech/Sci/R&D Officer 53 -
Director TitleAgeSince
Director/Board Member 54 26/10/2025
Director/Board Member 56 26/10/2025
Director/Board Member 51 26/10/2025
Change 5-day change 1-year change 3-year change Capi.($)
+11.50%-.--%-14.41%-77.80% 41.14M
+1.29%+3.46%+6.43%+16.36% 49.47B
+0.89%+13.44%+491.34%+594.30% 43.97B
+3.08%+14.42%+24.57%+81.39% 39.6B
+1.38%+3.70%+34.54%+9.11% 39.29B
+0.85%+10.32%+21.22%+47.64% 32.43B
+0.08%+5.00% - - 16.84B
+1.99%+5.08%+38.70%+125.08% 16.49B
+0.34%+3.40%+5.39%+18.79% 14.01B
+3.56%+19.98%+86.23%+27.29% 12.77B
Average +2.50%+6.44%+77.11%+93.57% 26.49B
Weighted average by Cap. +1.48%+7.06%+107.86%+140.03%
Logo Aptamer Sciences Inc
Aptamer Sciences Inc is a Korea-based company principally engaged in the research and development of bio therapeutic drugs. The Company provides services include aptamer synthesis and aptamer discovery. The Company also develops biopharmaceuticals such as insulin substitutes, insulin sensitizers, and liver cancer drugs. In addition, the Company also produces lung cancer diagnostic kits.
Employees
-
  1. Stock Market
  2. Stocks
  3. A291650 Stock